A. Shenoy

发表

Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab.

N. Young, Catherine Lai, C. Hourigan, 2019, Blood Advances.

Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation.

A. Barrett, R. Childs, B. Savani, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical and Biological Predictors of Outcome Following Relapse of Chronic Myeloid Leukemia after Allogeneic Stem Cell Transplantation

K. Rezvani, P. Muranski, K. Keyvanfar, 2014, Bone marrow transplantation.

Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19

W. Self, G. Bernard, A. Ginde, 2022, Chest.

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma

A. Casadevall, B. Lau, D. Hanley, 2021, medRxiv.

How do I implement an outpatient program for the administration of convalescent plasma for COVID‐19?

A. Casadevall, D. Hanley, Nichol McBee, 2022, Transfusion.

Clinical and biological predictors of outcome following relapse of CML post-allo-SCT

P. Muranski, K. Keyvanfar, C. Hourigan, 2015, Bone Marrow Transplantation.

The impact of environmental UV exposure on the clinical course of Mycosis Fungoides.

S. Fernandez, S. Desale, A. Shenoy, 2019, Journal of the American Academy of Dermatology.

ON 01910.Na Suppresses Cyclin D1 Accumulation in trisomy 8 Myelodysplastic Syndromes Patients While Decreasing Bone Marrow CD34+ Blast Counts and Aneuploid Clone Size.

P. Scheinberg, J. Groopman, A. Raza, 2009 .

Single center analysis of characteristics and outcomes of de novo, concurrent and transformed Diffuse Large B Cell Lymphoma.

Sanjal H Desai, A. Shenoy, R. Hameed, 2021, The oncologist.

Suppression of Cyclin D 1 (CD1) by on 01910.Na Is Associated with Decreased Survival or Trisomy 8 Myelodysplastic Bone Marrow: A Potential Targetted Therapy for Trisomy 8 MDS.

N. Young, E. Sloand, L. Pfannes, 2008 .

Alemtuzumab Is Safe and Associated With High Response Rates In Selected Patients With Myelodysplastic Syndrome

N. Young, C. Hourigan, P. Scheinberg, 2013 .

The Level of Minimal Residual Disease in Primitive Progenitor Cells from CML Patients after Allogeneic Stem Cell Transplantation Is Higher Than after Treatment with Tyrosine Kinase Inhibitors.

K. Rezvani, K. Keyvanfar, A. Barrett, 2008 .

Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection

A. Casadevall, S. Cramer, O. Laeyendecker, 2022, JCI insight.

Hypersensitivity to romidepsin.

J. Desimone, A. Shenoy, Rohit Kakar, 2014, Journal of the American Academy of Dermatology.

Early Outpatient Treatment for Covid-19 with Convalescent Plasma

A. Casadevall, B. Lau, D. Hanley, 2022, The New England journal of medicine.

Prolonged chronic graft-versus-host disease is a risk factor for thyroid failure in long-term survivors after matched sibling donor stem cell transplantation for hematologic malignancies.

A. Barrett, B. Savani, S. Goodman, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Recovery of spermatogenesis after total-body irradiation.

A. Barrett, B. Savani, A. Shenoy, 2006, Blood.

Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

N. Young, P. Scheinberg, A. Barrett, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation--implications for screening and HPV vaccination.

A. Barrett, P. Stratton, B. Savani, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Lamivudine prophylaxis and hepatitis B vaccination for prevention of hepatitis B virus reverse seroconversion in long-term survivors after allogeneic stem cell transplantation.

R. Childs, B. Savani, A. Shenoy, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Management of post‐transplant lymphoproliferative disorders

A. Shenoy, J. Catlett, C. DeStefano, 2018, British journal of haematology.

T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome.

K. Rezvani, A. Barrett, R. Childs, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation.

R. Srinivasan, K. Rezvani, A. Barrett, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Functional characterization of natural telomerase mutations found in patients with hematologic disorders.

Yuying Liang, Peter M Lansdorp, Adam Beauchamp, 2007, Blood.

Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial.

W. Quint, Sarah Wagner, M. Schiffman, 2020, JAMA oncology.

Early mortality benefit with COVID‐19 convalescent plasma: a matched control study

A. Hettinger, S. Fernandez, J. Blumenthal, 2021, British journal of haematology.

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.

N. Young, P. Scheinberg, E. Sloand, 2012, Leukemia research.

Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation.

D. Douek, B. Hill, K. Keyvanfar, 2011, Blood.

Alemtuzumab as initial therapy for Sézary syndrome: A report of 2 cases

S. Ronkainen, K. Saardi, A. Shenoy, 2020, JAAD case reports.

Antibody Correlates of Protection for COVID-19 Convalescent Plasma Associated with Reduced Outpatient Hospitalizations

A. Casadevall, B. Lau, L. Appel, 2023, medRxiv.

DA-EPOCH-R Has Comparable Outcomes in De Novo and Transformed Diffuse Large B Cell Lymphoma

A. Shenoy, R. Hameed, M. Chaturvedi, 2020 .

Robust Expansion of Viral Antigen-specific CD4+ and CD8+ T Cells for Adoptive T Cell Therapy Using Gene-modified Activated T Cells as Antigen Presenting Cells

K. Keyvanfar, J. Melenhorst, N. Hensel, 2006, Journal of immunotherapy.

Recombinant factor VIIa to treat diffuse alveolar hemorrhage following allogeneic stem cell transplantation.

B. Savani, A. Barrett, A. Shenoy, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study

A. Casadevall, O. Laeyendecker, L. Hammitt, 2023, The Lancet. Microbe.

Ifosfamide-Induced Metabolic Encephalopathy in 2 Patients With Cutaneous T-Cell Lymphoma Successfully Treated With Methylene Blue

J. Joseph, Anusha Vakiti, A. Shenoy, 2018, Journal of investigative medicine high impact case reports.

Transfusion reactions associated with COVID‐19 convalescent plasma in outpatient clinical trials

David M. Shade, A. Casadevall, B. Lau, 2023, Transfusion.